


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Hawaii Pacific Health, Inc.</p> <p>2. 98-1079 Moanalua Road Aiea, HI 96701</p>	<p>In accordance with letter dated September 13, 2022; and email dated September 17, 2022,</p>	<p>4. Expiration Date: August 31, 2025</p>
	<p>3. License No.: 53-23297-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-31200 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. No single container to exceed 300 millicuries and 3.3 curies total	C. For any use permitted by 10 CFR 35.300.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 53-23297-01

Docket or Reference No.:
030-31200

Amendment No. 41

- | | | | |
|--|---|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>D. Any byproduct material permitted in 10 CFR 35.400</p> | <p>7. Chemical and/or physical form</p> <p>D. Sealed Sources (Best Medical International, Inc., Model 2300 Series; CivaTech Oncology, Inc., Model CivaString; Core Oncology, Inc., Model I-125SL; IsoStar Texas, Inc. dba Imagyn Medical Technologies, Model IS-12501; IsoAid, L.L.C., Model IAPd-103A (Advantage Pd-103) or IAI-125A; Medi-Physics, Inc., Model 6702, 6711 (OncoSeed), 6733 (EchoSeed), or 6735; North American Scientific, Inc., Model MED3633 or 3631; Theragenics Corp., Model AgX100 or TheraSeed 200)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>D. 1 curie total</p> | <p>9. Authorized use</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</p> |
|--|---|---|--|



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 53-23297-01

Docket or Reference No.:
030-31200

Amendment No. 41

CONDITIONS

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.D. shall be used or stored at the licensee's facilities located at Pali Momi Medical Center, 98-1079 Moanalua Road, Aiea, Hawaii (Island of Oahu), and
- B. Licensed material identified in Items 6.A. through 6.C. shall be used or stored at the licensee's facilities located at Kapi'olani Medical Center for Women and Children, 1319 Punahou Street, Honolulu, Hawaii (Island of Oahu).
11. The Radiation Safety Officer (RSO) for this license is Ronald W. Frick, M.S., CHP, DABR.
12. Licensed material shall only be used by, or under the supervision and in the physical presence of:
- A. Individuals permitted to work as authorized users, authorized nuclear pharmacists, and/or authorized medical physicists in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized Users</u> | <u>Material and Use</u> |
|-------------------------------|---|
| David S. Ansdell, M.D. | 35.100; 35.200; Oral administration of sodium iodide I-131 |
| Jeffrey M. Bender, M.D. | 35.200 |
| Michael W. Chan, M.D. | 35.200 |
| Susie Ann Chen, M.D. | 35.400 |
| Andy K. Chon, M.D. | 35.100; 35.200; Oral administration of sodium iodide I-131 |
| Sanah Christopher, M.D. | 35.200 |
| Stephen E. Darling, M.D. | 35.100; 35.200; Oral administration of sodium iodide I-131 |
| Kim Mika Fujinaga, M.D. | 35.100; 35.200; Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries |
| Lee N. Goerner, M.D. | 35.100; 35.200; Oral administration of sodium iodide I-131 |
| Mitchell T. Gudmundsson, M.D. | 35.100; 35.200; Oral administration of sodium iodide I-131 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 53-23297-01

Docket or Reference No.:
030-31200

Amendment No. 41

Authorized UsersMaterial and Use

Bryan Gushiken, M.D.

35.100; 35.200

Panupong Jiamsripong, M.D.

35.200

Kevin N. Kon, M.D.

35.100; 35.200

John Lederer, M.D.

35.400

Richard Y Lee, M.D.

35.400

Zachary B. Love, M.D.

35.100; 35.200; Oral administration of sodium iodide I-131

Laeton Pang, M.D.

35.400

Rajiv Girish Rao, M.D.

35.100; 35.200; Oral administration of sodium iodide I-131

Michael Charles Roach, M.D.

35.400

Christina Koo Speirs, M.D.

35.400

Charles N. Weber, M.D.

35.100; 35.200; Oral administration of sodium iodide I-131

13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 53-23297-01

Docket or Reference No.:
030-31200

Amendment No. 41

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated April 1, 2015 (ML15117A175)
- B. Letter dated August 14, 2015 (ML15227A004)
- C. Letter dated August 5, 2016 (ML16231A400)
- D. Application dated January 31, 2018 (ML18053A890)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 19, 2022By: _____
Roberto J. Torres
Region IV